1. Home
  2. SCYX vs JL Comparison

SCYX vs JL Comparison

Compare SCYX & JL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • JL
  • Stock Information
  • Founded
  • SCYX 1999
  • JL 1985
  • Country
  • SCYX United States
  • JL Hong Kong
  • Employees
  • SCYX N/A
  • JL N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • JL
  • Sector
  • SCYX Health Care
  • JL
  • Exchange
  • SCYX Nasdaq
  • JL NYSE
  • Market Cap
  • SCYX 28.5M
  • JL 23.3M
  • IPO Year
  • SCYX 2014
  • JL 2024
  • Fundamental
  • Price
  • SCYX $0.82
  • JL $6.76
  • Analyst Decision
  • SCYX
  • JL
  • Analyst Count
  • SCYX 0
  • JL 0
  • Target Price
  • SCYX N/A
  • JL N/A
  • AVG Volume (30 Days)
  • SCYX 176.2K
  • JL 14.3K
  • Earning Date
  • SCYX 08-07-2025
  • JL 07-22-2025
  • Dividend Yield
  • SCYX N/A
  • JL N/A
  • EPS Growth
  • SCYX N/A
  • JL N/A
  • EPS
  • SCYX N/A
  • JL 0.54
  • Revenue
  • SCYX $2,630,000.00
  • JL $32,831,195.00
  • Revenue This Year
  • SCYX $463.61
  • JL N/A
  • Revenue Next Year
  • SCYX $310.80
  • JL N/A
  • P/E Ratio
  • SCYX N/A
  • JL $11.97
  • Revenue Growth
  • SCYX N/A
  • JL 7.72
  • 52 Week Low
  • SCYX $0.66
  • JL $2.33
  • 52 Week High
  • SCYX $2.29
  • JL $13.41
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 57.87
  • JL 65.04
  • Support Level
  • SCYX $0.67
  • JL $6.00
  • Resistance Level
  • SCYX $0.75
  • JL $6.50
  • Average True Range (ATR)
  • SCYX 0.04
  • JL 0.37
  • MACD
  • SCYX 0.01
  • JL -0.02
  • Stochastic Oscillator
  • SCYX 93.53
  • JL 55.41

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About JL J-LONG GROUP LIMITED

J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.

Share on Social Networks: